title: Combinations of targeted therapies take aim at multiple pathways.
authors: Bruce
authors: B
authors: Goldman
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology; D001549:Benzamides; D001897:Boronic Acids / Q000494:pharmacology; D000069286:Bortezomib; D002986:Clinical Trials as Topic; D000077156:Gefitinib; D006801:Humans; D000068877:Imatinib Mesylate; D009369:Neoplasms / Q000188:drug therapy*; D010879:Piperazines / Q000494:pharmacology; D011719:Pyrazines / Q000494:pharmacology; D011743:Pyrimidines / Q000494:pharmacology; D011799:Quinazolines / Q000494:pharmacology; D012107:Research Design
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D001897:Boronic Acids; D010879:Piperazines; D011719:Pyrazines; D011743:Pyrimidines; D011799:Quinazolines; D000069286:Bortezomib; D000068877:Imatinib Mesylate; D000077156:Gefitinib